https://t.co/8ygWFxK8RI Complement inhibition has translated beautifully and broadly, a prediction on which you could've generated alpha for a decade w/ out getting anything else right. a-beta oligomers moving in right direction. we'll learn more soon abo
Pubmed hits: Glucose - 600,000 Amyloid beta - 67,000 Malonaldehyde - 66,000 P2X3 - 1,371 Pubmed hits in 2021: Malonaldehyde - 5,577 P2X3 - 79 P2X3 programs - many, valued over >$1b Malonaldehyde traps - 1 (?), valued at nothing
The two targets/programs with the largest gap between the apparent evidence in the literature vs apparent belief in the literature are beta-amyloid oligomers $ABOS & RASP (malonaldehyde being best studied species & proxy) $ALDX. https://t.co/D1UD
Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis #SLE #jirsecondaryantibodies #ELISA https://t.co/YYYR4sduXp